Proteome profiling of urinary exosomes identifies alpha 1-antitrypsin and H2B1K as diagnostic and prognostic biomarkers for urothelial carcinoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Lin, Shih Yi ^a,b   Chang, Chao Hsiang ^b   Wu, His Chin ^b   Lin, Ching Chan ^a,b   Chang, Kai Po ^b   Yang, Chi Rei ^b   Huang, Chi Ping ^a,b   Hsu, Wu Huei ^a,b   Chang, Chiz Tzung ^a,b   Chen, Chao Jung ^b,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84989954130     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep34446     Document Type: Article

References (46)

1. Ploeg, M., Aben, K. K. H. and Kiemeney, L. A. The present and future burden of urinary bladder cancer in the world. World J Urol. 27, 289-293 (2009).
2. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 64, 639-653 (2013).
3. Palou, J. et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol. 174, 859-861 (2005).
4. Raitanen, M.-P. et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol. 41, 284-289 (2002).
5. Y., Lotan and C. G., Roehrborn. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol. 167, 75-79 (2002).
6. Schiffer, E. et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin Cancer Res. 15, 4935 (2009).
7. Shimwell, N. et al. Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma. Br J Cancer 108, 1854 (2013).
8. Yang, N. et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res. 17, 3349 (2011).
9. Gruenberg, J. and Stenmark, H. The biogenesis of multivesicular endosomes. Nat Rev Mol Cell Biol. 5, 317 (2004).
10. Thery, C., Zitvogel, L. and Amigorena, S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2, 569 (2002).
11. Beckham, C. J. et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol. 192, 583 (2014).
12. Hoorn, E. J. et al. Prospects for urinary proteomics: Exosomes as a source of urinary biomarkers. Nephrology 10, 283 (2005).
13. Welton, J. L. et al. Proteomic analysis of bladder cancer exosomes. Mol Cell Proteomics 9, 1324-1338 (2010).
14. Chen, C.-L. et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res. 11, 5611-5629 (2012).
15. Cheruvanky, A. et al. Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am J Physiol Renal Physiol. 292, F1657-F1661 (2007).
16. Kulasingam, V. and Diamandis, E. P. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 5, 588-599 (2008).
17. Oppenheim, J., Biragyn, A., Kwak, L. and Yang, D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis. 62, ii17-ii21 (2003).
18. Pisitkun, T., Shen, R.-F. and Knepper, M. A. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA 101, 13368-13373 (2004).
19. Gonzales, P. A. et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol. 20, 363-379 (2009).
20. Raj, D. A., Fiume, I., Capasso, G. and Pocsfalvi, G. A multiplex quantitative proteomics strategy for protein biomarker studies in urinary exosomes. Kidney Int. 81, 1263-1272 (2012).
21. Wu, C.-C. et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Mol Cell Proteomics. 9, 1100-1117 (2010).
22. Hosseini-Beheshti, E., Pham, S., Adomat, H., Li, N. and Guns, E. S. Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes. Mol Cell Proteomics. 11, 863-885 (2012).
23. Candiano et al. Repetitive Fragmentation products of albumin and a 1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol. 17, 3139-3148 (2006).
24. Siwy, J., Mullen, W., Golovko, I., Franke, J. and Zurbig, P. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl. 5, 367-374 (2011).
25. Hunt, J. M. and Tuder, R. Alpha 1 anti-trypsin: one protein, many functions. Curr Mol Med. 12, 827-835 (2012).
26. Rudnick, D. A. and Perlmutter, D. H. Alpha-1-antitrypsin deficiency: A new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology 42, 514-521 (2005).
27. Yang, P. et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 168, 1097-1103 (2008).
28. Sun, Z. and Yang, P. Role of imbalance between neutrophil elastase and a 1-antitrypsin in cancer development and progression. Lancet Oncol. 5, 182-190 (2004).
29. Hamrita, B. et al. Proteomics-based identification of a 1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clinica Chimica Acta 404, 111-118 (2009).
30. Kuvibidila, S. and Rayford, W. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer. Transl Res. 147, 174 (2006).
31. Rajendiran, S. et al. MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Mol Cancer 13, 1 (2014).
32. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49, 466-477 (2006).
33. Clague, M. J., Coulson, J. M. and Urbe, S. Deciphering histone 2A deubiquitination. Genome Biol 9, 202 (2008).
34. Cole, A. J., Clifton-Bligh, R. and Marsh, D. J. Histone H2B monoubiquitination: roles to play in human malignancy. Endocr Relat Cancer. 22, T19-T22 (2015).
35. Kondo, Y. and Issa, J.-P. J. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 23, 29 (2004).
36. DArcy, P., Wang, X. and Linder, S. Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther. 147, 32-54 (2015).
37. Telu, K. H. et al. Alterations of histone H1 phosphorylation during bladder carcinogenesis. J Proteome Res. 12, 3317-3326 (2013).
38. Loddo, M. et al. Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer 100, 959-970 (2009).
39. Bonenfant, D. et al. Analysis of dynamic changes in post-translational modifications of human histones during cell cycle by mass spectrometry. Mol Cell Proteomics 6, 1917-1932 (2007).
40. Fromont, G. et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol. 48, 764-770 (2005).
41. Nakanishi, K. et al. Expression of hypoxia-inducible factor-1a protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res. 11, 2583-2590 (2005).
42. Shariat, S. F. et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 15, 7012-7019 (2009).
43. Saito, K. et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU international.l 100, 269-273 (2007).
44. Lotan, Y. et al.Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol. 64, 465-471 (Sep, 2013).
45. Fernandez-Llama, P. et al. Tamm-Horsfall protein and urinary exosome isolation. Kidney Int. 77, 736-742 (2010).
46. Zhou, H. et al. Collection, storage, preservation, and normalization of human urinary exosomes for biomarker discovery. Kidney Int. 69, 1471-1746 (2006).